CEO REMARKS 2026 AGM

12 November 2026

In accordance with Listing Rule 3.13.3, please see the remarks to be presented at the Tetratherix Limited (ASX:TTX) (**Tetratherix**) 2026 AGM by Will Knox our CEO.

A year ago we listed on the ASX with a clear thesis and FY26 was the year we put it to work. The thesis was simple, and to some it sounded unconventional. One chemistry, invented and made in Sydney, programmed into many products and carried into the world by the strongest partner in each field. Fifteen years of work went into that chemistry and FY26 has laid the foundation for that thesis to propel us into the future of healthcare upon our Tetramatrix innovation – the building blocks for medicine.

We completed our first full FDA submissions in our bone regeneration franchise. Behind them sit twenty-seven technical reports, the complete ISO 10993 safety package and two FDA performance studies. In our precision medicine program, the FDA has also now assigned the Tetramatrix polymer its own federal identifier as a approved excipient as we begin to change the way drugs and biologics are delivered in metabolic health & consumer medicine. The progress we have made in bringing an entirely new chemical entity to the world's most rigorous regulator speaks to the work that has been done behind the scenes, over many years with world leading researchers – the significance of which can not be overstated.

In FY26 We became a revenue-generating company. Our precision medicine program has launched with sophisticated partnerships building commercial and technical infrastructure. We signed an exclusive global supply agreement with Henry Schein, one of the largest medical and dental companies in the world. We licensed our ophthalmic technology to BioOptix, which has partnered with Alcon – the leading player in the ophthalmic space globally, with whom our Optimatrix program is being executed.

Our clinical evidence compounded. Tutelix completed its first-in-human pilot study with no product-related adverse events and proven efficacy aligned with our design & development objectives, and holds ethics approval for its pivotal trial that is getting underway in 2026. TetraDerm completed its full enrolment and has moved into the largest wounds in surgery with blinded results coming in 2027 in line with the opening of our strategic partnership window. More than 75 patients have now been treated with Tetramatrix, a 58 per cent increase on the year before. And five years of quiet work in nasal drug delivery became a new franchise, Precision Medicine, with STEPP at its centre.

All of this has been done on budget and slightly ahead of time for many programs which speaks to our execution-focused culture at TTX. We closed the year with $34.4 million in cash, having secured more than $20 million beyond our prospectus assumptions.

The economics of this company are the part of our story I believe compounds our differentiation and are deliberately designed to scale. Our six first-generation products come from three polymer configurations that share around 95 per cent of their chemistry. Our partners carry regulation, reimbursement and distribution in their own markets. As they sequentially launch over the coming years, each new partner adds revenue onto the same core chemistry, the same safety data and the same production line. We built Tetratherix to be capital-light by design. Over the coming years, as licence income is joined by product supply, that design will show up in our numbers.
FY27 is the year our science turns into revenue, and the platform reaches several inflection points at once.

© Tetratherix Limited 2026

The first is commercialisation. We are rapidly working toward FDA clearance for our bone regeneration products, followed by a disciplined US seeding program across dental as well as orthopaedics and our first regenerative product sales. STEPP is well placed for its commercial polymer supply as the precision medicine franchise builds.

The second is platform growth. Tutelix will enrol its first pivotal trial patients. Optimatrix rapidly moves toward the clinic. In orthopaedics, TegenEOS extends into platelet-rich plasma delivery, where our recent preclinical tendon results point to simpler, earlier treatment in ambulatory settings, which has guided our orthopaedic partnership due diligence program in FY26.

Following, the third is new partners. We are selecting a long-term strategic partner for TegenEOS, and conversations across the rest of the platform deepened through the year, specifically in precision medicine and tissue healing as TetraDerm proved itself as a healing innovation. We choose partners for a fifteen-to-twenty-year horizon, and we will announce them when the work is complete, aligned with our long term, compounding strategy.

The fourth is the transition to commercial supply and revenue itself. Our advanced manufacturing campus in Alexandria brings headquarters and production under one roof and lifts our capacity tenfold. With MDSAP certification now officially installed into the system, it opens the United States, Australia and other major markets together as we grow the supply capabilities for our partners.

Every result I have described belongs to our people. A team of less than 30 people took a research house and evolved it into a manufacturing-led commercial company inside a single year. The same scientists who defined our design & development systems now run qualified production lines, sit across the table from regulators and hold global partners to the standard our science demands. To every member of the Tetratherix team: you are remarkable, and I am immensely proud to work beside you.

The market rewards conviction when evidence stands behind it. We intend to keep supplying both. To our shareholders – thank you. Thank you for your support, aligned vision on what medicine should look like and your belief in us. Our mission is to treat ten million patients by 2035 and each of them will receive care that is faster, gentler and safer because you backed this company early. That is what your capital is building.

< ENDS >

InvestorHub

The Tetratherix InvestorHub platform provides existing and prospective shareholders with real-time access to ASX announcements, reports and presentations. You can visit the Tetratherix Investor Hub at:

InvestorHub

Authorised for release by the CEO.

For further information contact:
Jacob Pfeffer
General Counsel | Chief of Staff | Company Secretary
+61 425 194 200
jacob.pfeffer@tetratherix.com

© Tetratherix Limited 2026